AstraZeneca's (AZN) Lynparza Gets Another Orphan Drug Status Zacks Equity Research - Zacks Investment Research - Tue Oct 16, 2:48PM CDT Zacks Equity Research - ZACKS - Tue Oct 16, 2:48PM CDT
AstraZeneca (AZN) and partner Merck's Lynparza receive Orphan Drug designation (ODD) by the FDA for the treatment of pancreatic cancer.
3 Large-Cap Pharma Stocks Performing Better Than Industry Zacks Equity Research - Zacks Investment Research - Fri Oct 12, 9:12AM CDT Zacks Equity Research - ZACKS - Fri Oct 12, 9:12AM CDT
We focus on three large-cap pharma stocks that are outperforming the industry on the back of their diverse portfolio.
J&J (JNJ) Gets FDA Approval for Xarelto Label Expansion Zacks Equity Research - Zacks Investment Research - Fri Oct 12, 9:04AM CDT Zacks Equity Research - ZACKS - Fri Oct 12, 9:04AM CDT
Johnson & Johnson's (JNJ) Xarelto gets FDA approval for reducing risk of major cardiovascular events in chronic coronary or peripheral artery disease patients.
Merrimack (MACK) Focuses on Early Stage Pipeline and Cost Cuts Zacks Equity Research - Zacks Investment Research - Thu Oct 11, 4:16PM CDT Zacks Equity Research - ZACKS - Thu Oct 11, 4:16PM CDT
Merrimack (MACK) focuses on the development of its two early-stage pipeline candidates, MM-121 and MM-310. The candidates have been progressing well and are imperative to the company's growth.
Immune Checkpoint Inhibitors Market is Anticipated to Cross US$ 25 Billion by 2022 Due to Increasing Prevalence of Cancer and Immune Diseases: Radiant Insights, Inc. PR Newswire - Wed Oct 10, 7:10AM CDT CMTX - Wed Oct 10, 7:10AM CDT
The global Immune Checkpoint Inhibitors Market is likely to witness a higher CAGR in the forecast period. Oncology is a wide field with various diagnoses and applications. Increase in cancer cases and...
Top Research Reports for JPMorgan, American Express & FedEx Mark Vickery - Zacks Investment Research - Tue Oct 9, 1:34PM CDT Mark Vickery - ZACKS - Tue Oct 9, 1:34PM CDT
Top Research Reports for JPMorgan, American Express & FedEx
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)? Sweta Killa - Zacks Investment Research - Tue Oct 9, 10:39AM CDT Sweta Killa - ZACKS - Tue Oct 9, 10:39AM CDT
Sector ETF report for PPH
5 Reasons Why Investors Should Bet on Merck (MRK) Stock Zacks Equity Research - Zacks Investment Research - Mon Oct 8, 7:56AM CDT Zacks Equity Research - ZACKS - Mon Oct 8, 7:56AM CDT
Here are some reasons why investors may consider putting their money into Merck (MRK) stock.
Pharma Stock Roundup: PFE to Get New CEO, LLY Presents Impressive Diabetes Data Zacks Equity Research - Zacks Investment Research - Fri Oct 5, 8:57AM CDT Zacks Equity Research - ZACKS - Fri Oct 5, 8:57AM CDT
Pfizer (PFE) CEO, Ian Read to be replaced by present chief operating officer. Pipeline updates from Lilly (LLY), Novartis (NVS), J&J (JNJ) and others.
Lilly's Novel Diabetes Candidate Shows Promise in Phase II Zacks Equity Research - Zacks Investment Research - Fri Oct 5, 8:54AM CDT Zacks Equity Research - ZACKS - Fri Oct 5, 8:54AM CDT
Lilly's (LLY) dual GIP and GLP-1 receptor agonist demonstrates impressive reduction in blood sugar levels as well as body weight in type II diabetes patients.
Dow 30 Stock Roundup: Boeing Wins $9.2B Pilot Training Deal, Intel Keeps '18 View Swarup Gupta - Zacks Investment Research - Fri Oct 5, 8:11AM CDT Swarup Gupta - ZACKS - Fri Oct 5, 8:11AM CDT
The index advanced strongly this week before suffering a sharp decline on Thursday.
Clovis' Rubraca Gets Breakthrough Therapy Status for mCRPC Zacks Equity Research - Zacks Investment Research - Wed Oct 3, 10:37AM CDT Zacks Equity Research - ZACKS - Wed Oct 3, 10:37AM CDT
Clovis' (CLVS) cancer drug, Rubraca, gets Breakthrough Therapy designation from the FDA for treating metastatic castration resistant prostate cancer with BRCA mutation.
QIAGEN's FDA Nod for Expanded EGFR Test Use Widens Suite Zacks Equity Research - Zacks Investment Research - Tue Oct 2, 8:14AM CDT Zacks Equity Research - ZACKS - Tue Oct 2, 8:14AM CDT
QIAGEN (QGEN) continues to expand test menu; latest FDA approval to boost portfolio.
DSRLF : 92.9300 (-14.14%) Roche Gets FDA Approval for New Formulation of Asthma Drug Zacks Equity Research - Zacks Investment Research - Mon Oct 1, 1:56PM CDT Zacks Equity Research - ZACKS - Mon Oct 1, 1:56PM CDT
Roche (RHHBY) receives FDA approval for a dose prefilled syringe (PFS) formulation of its asthma drug, Xolair.
Sanofi/Regeneron's Cemiplimab Wins FDA Nod for Skin Cancer Zacks Equity Research - Zacks Investment Research - Mon Oct 1, 10:35AM CDT Zacks Equity Research - ZACKS - Mon Oct 1, 10:35AM CDT
Sanofi (SNY)/Regeneron's (REGN) anti- PD-1 drug cemiplimab wins FDA approval for a type of skin cancer.
Pfizer's (PFE) Lung Cancer Drug Vizimpro Gets FDA Approval Zacks Equity Research - Zacks Investment Research - Fri Sep 28, 9:54AM CDT Zacks Equity Research - ZACKS - Fri Sep 28, 9:54AM CDT
The FDA approves Pfizer's (PFE) Vizimpro for first-line treatment of locally advanced or metastatic non-small cell lung cancer in patients with epidermal growth factor receptor activating mutations.
Pharma Stock Roundup: PFE, LLY Get Approval for New Drugs, Novartis to Cut Jobs Zacks Equity Research - Zacks Investment Research - Fri Sep 28, 9:07AM CDT Zacks Equity Research - ZACKS - Fri Sep 28, 9:07AM CDT
FDA grants approval to Lilly's (LLY) Emgality for migraine and Pfizer's (PFE) Vizimpro for an advanced lung cancer indication. Novartis (NVS) to cut more than 2,000 jobs in Switzerland and U.K
Report: Developing Opportunities within AstraZeneca, Manulife Financial, Infosys, Novartis AG, Black Hills, and Shell Midstream Partners -- Future Expectations, Projections Moving into 2018 GlobeNewswire - Fri Sep 28, 7:00AM CDT CMTX - Fri Sep 28, 7:00AM CDT
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of AstraZeneca PLC (NYSE:AZN),...
Allergan Eyes Vraylar Label Expansion, FDA Accepts sNDA Zacks Equity Research - Zacks Investment Research - Thu Sep 27, 2:10PM CDT Zacks Equity Research - ZACKS - Thu Sep 27, 2:10PM CDT
FDA accepts Allergan's (AGN) sNDA for label expansion of its schizophrenia drug, Vraylar (cariprazine) to include treatment of bipolar depression.
Company News For Sep 26, 2018 Zacks Equity Research - Zacks Investment Research - Wed Sep 26, 9:26AM CDT Zacks Equity Research - ZACKS - Wed Sep 26, 9:26AM CDT
Companies in the news are:
FDS, SONC, AZN and EVHC
